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Abstract
Background: Freeman-Sheldon and Sheldon-Hall syndromes (FSS and SHS) and distal arthrogryposis types 1 and 3
(DA1 and DA3) are rare, often confused, congenital syndromes. Few studies exist. With reported diagnosis
unreliable, it would be scientifically inappropriate to consider articles describing FSS, SHS, DA1, or DA3, unless
diagnoses were independently verified, rendering conventional systematic review and meta-analysis methodology
inappropriate and necessitating patient-level data analysis (PROSPERO: CRD42015024740).
Methods/design: As part of a clinical practise guideline development process, we evaluate (1) diagnostic accuracy
from 1938–2017, using the Stevenson criteria; (2) the most common physical findings, possible frequency clusters,
and complications of physical findings amongst patients with FSS; and (3) treatment types and outcomes. All
papers reporting diagnosis of FSS, SHS, DA1, and DA3 are included in searching PubMed and Google Scholar from
December 2014 to July 2015 and again before final analyses. Patients with FSS are divided into four phenotype-
defined sub-types; all patients are grouped by published diagnosis and medical speciality. Significance of physical
findings and historical data is evaluated by chi-square. Associations of physical findings and history with diagnosis
and treatment outcome are evaluated by Pearson correlation and linear regression analysis. Two-tailed alpha level
of 0.05 is used throughout.
Discussion: The need for detailed patient-level data extraction may limit the types of articles included and
questions able to be answered. For treatment and psychosocial health outcomes, we anticipate enhanced
difficulties, which may limit significance, power, and results’ usability. We hope to outline knowledge gaps and
prioritise areas for clinical investigation.
Systematic review registration number: CRD42015024740
Universal Trial Number: U1111-1172-4670
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Introduction
First described by Freeman and Sheldon [1], Freeman-
Sheldon and Sheldon-Hall syndromes (FSS and SHS) are
highly variable, rare, phenotypically similar but genotypi-
cally distinct, and often confused congenital myopathies,
despite previous attempts to simplify diagnosis [2].
While Antley et al. (1970) completed a systematic review
and statistical analysis of patient-level clinical informa-
tion from published reports, allelic variation data were
not available, and few cases were available for analysis
[2]. Stevenson et al. (2006) executed a cohort study of
geneticist-referred patients with classic FSS and SHS [3],
which limited their cohort, but they were able to define
meaningful and strict clinical diagnostic criteria for FSS
and SHS. For FSS, they required the following: microsto-
mia, whistling-face appearance (pursed lips), H or V-
shaped chin dimpling, prominent nasolabial folds, and
major contractures in two or more body regions [3]. For
SHS, they required the following: small mouth (not
microstomia), prominent nasolabial folds, small but
prominent chin, neck webbing, and major contractures
in two or more body regions [3].
In FSS, spinal deformities, metabolic and gastroentero-
logical problems, other dysmorphic craniofacial charac-
teristics, and visual and auditory impairments are
frequent findings [2, 3]. Some individuals present with
minimal malformation; rarely, patients die during in-
fancy as a result of severe central nervous system in-
volvement or respiratory complications. While patients
with classic FSS have normal intelligence, a genotypically
distinct lethal variant characterised by profound and
progressive neurological motor and cognitive impair-
ment exists [4]. For FSS and SHS, the most familial cases
are by autosomal dominant inheritance, but expression
is often from new allelic variation [3]. Frequency of it is
unknown, mostly due to diagnostic uncertainty; there
appears to be neither sex nor ethnic preference. Environ-
mental and parental factors are not implicated in
pathogenesis.
No systematic review has been completed since the
genotype-verified clinical diagnostic criteria [5, 6] were
published. Unfortunately, few studies involving either or
both FSS and SHS exist, and with reported diagnosis
unreliable, it would be scientifically inappropriate to
consider articles describing FSS or SHS, unless diagnoses
were independently verified. Thus, a conventional sys-
tematic review and meta-analysis methodology was in-
appropriate in this instance, and rigorous patient-level
clinical information extraction and aggregation was
required.
The systematic review and patient-level data meta-
analysis objectives are as follows: to (1) determine diag-
nostic accuracy from 1938–2017, using the Stevenson
criteria [3]; (2) define the most common physical
findings, possible frequency clusters and complications
of physical findings amongst patients with FSS; and (3)
document treatment types and outcomes. Additionally, a
myriad of phenotypes are described as FSS—further
complicating literature searches and clinical practise
guideline development. To evaluate possible differences
with patients meeting and those not meeting the full
Stevenson criteria [3], we group phenotypes fulfilling the
craniofacial part of the Stevenson criteria [3] according
to presence or absence of limb malformations. While the
focus is on FSS and SHS, patients rediagnosed by review
authors with the phenotypically similar conditions distal
arthrogryposis types 1A, 1B, and 3 (DA1A, DA1B, and
DA3) are included. In this review, no distinction is made
between DA1A and DA1B, which are simply termed
DA1. DA1 shares the limb malformations of FSS and
SHS but lacks craniofacial features; DA3 or Gorden
syndrome is associated with cleft palate, as well as simi-
lar limb and skeletal malformations as FSS, SHS, and
DA1.
Methods and design
Undertaken as part of the unfunded Freeman-Sheldon
syndrome clinical practise guideline development
process sponsored by Freeman-Sheldon Research Group,
Inc., this systematic review and meta-analysis received
institutional review board (IRB) approval from FSRG
IRB #1 and was registered with the World Health Orgi-
nisation (U1111-1172-4670) and on PROSPERO
(CRD42015024740) (Additional file 1: PROSPERO Rec-
ord Public View), where subsequent amendments are
made available. The protocol, including development of
actionable clinical questions (Table 1), was prospectively
drafted in compliance with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses Protocols [7]
(Additional file 2: PRISMA-P 2015 Checklist), and all
data are reviewed for integrity and consistency by the
IRB’s biostatistician. Unless otherwise stated, all actions
undertaken are executed by the review authors.
Literature search
Material for consideration is identified by searching
PubMed and Google Scholar, from December 2014 to
July 2015, for all articles in any language relating to FSS,
SHS, DA1, and DA3. No advanced search features or
limits are used for PubMed because of the paucity of
available literature. For Google Scholar, search limits are
required because of its broader search inclusion;
searches on Google Scholar were limited to articles with
search terms appearing in the title. For PubMed (URL:
https://goo.gl/FOqJzn) and Google Scholar (URL: http://
bit.ly/2eoe1qj), search strategy (Table 2) includes all
known syndromic synonyms as search terms, including
distal arthrogryposis type 2A, distal arthrogryposis type
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2B, distal arthrogryposis multiplex congenita, Freeman-
Sheldon syndrome, Freeman-Sheldon, Sheldon-Hall
syndrome, whistling face syndrome, craniocarpotarsal
dystrophy, craniocarpotarsal dysplasia, cranio-carpo-
tarsal dystrophy, cranio-carpo-tarsal dysplasia and
cranio-facio-corporal syndrome. Searches are re-run
before final analyses, and articles published since the ini-
tial search are retrieved for inclusion.
Eligibility criteria
Because of the need for detailed patient-level clinical
information to meet objectives, articles meeting inclu-
sion criteria included are expected to be limited to
observational case reports, negating the utility of
evidence grading matrices such as Grading of Recom-
mendations Assessment, Development and Evaluation
[8]. No published article is excluded based on design
alone, however. Treatment comparison is expected to be
limited, as many articles describe neither interventions
nor outcomes; those that do cannot be confidently
Table 1 Actionable guiding clinical questions
1.For patients with suspected or confirmed FSS, SHS, DA1, or DA3,
is a craniofacial team, compared with individual speciality referrals,
reasonably expected to improve clinical care and to improve
achievement of overall treatment outcomes?
2.For patients with suspected FSS, do plastic surgeons, paediatricians,
clinical geneticists, orthopaedic surgeons, anaesthesiologists, or dental
surgeons have the highest diagnostic accuracy for FSS and should
therefore be the first referral option for providers suspecting a diagnosis
of FSS, according to the Stevenson criteria?
3.For patients with suspected FSS, SHS, DA1, and DA3, are there
non-overlapping definable feature (physical findings or historical data)
frequency clusters or individual features that are predictive of diagnosis
and that providers must be aware of to improve treatment-related
decision-making?
4.For patients with suspected or confirmed FSS, SHS, DA1, or DA3, are
there definable feature (physical findings or historical data) frequency
clusters or individual features that are predictive of treatment outcome
and that providers must be aware of to improve treatment-related
decision-making?
5.For patients with FSS, SHS, DA1, or DA3, is aggressive non-operative
therapy (e.g., braces, splints, passive manipulation), compared with
surgical correction, reasonably expected to improve achievement of
overall treatment outcomes?
6.For patients with suspected or confirmed FSS, SHS, DA1, or DA3, is
neurological consultation, compared with general evaluation, reasonably
expected to improve treatment-related decision-making (i.e., distinguishing
myopathic processes from primary neurological processes) and outcomes
(i.e., monitoring patients with craniosynostosis).
7.For patients and families affected by FSS, SHS, DA1, or DA3, is early
psychiatric consultation, compared with only a general explanation of
anticipated clinical course and treatment plans, appropriate to assist in
reducing psychosocial sequelae relevant to diagnosis burden?
8.For preschool and school-age patients with FSS, SHS, DA1, or DA3, is
intelligence testing, compared with subjective parent and teacher
observation, appropriate to assist in improving access to appropriate
academic services?
9.For patients with FSS, SHS, DA1, or DA3, is ophthalmological
consultation, compared with general evaluation, appropriate to assist in
improving reconstructive surgery-related decision-making and to im-
prove achievement of overall treatment outcomes?
10.For patients with FSS, SHS, DA1, or DA3, is otorhinolaryngology
consultation, compared with general evaluation, appropriate to assist in
improving reconstructive surgery and dysphagia-related decision-making
and to improve achievement of overall treatment outcomes?
11.For patients with FSS, SHS, DA1, or DA3, is paediatric dentistry and
oral-maxillofacial surgery referral, compared with general dentistry,
required to expect reasonable treatment-related decision-making and
reduce dental-related health burdens?
12.For patients with FSS, SHS, DA1, or DA3, is physiatry referral,
compared with orthopaedic surgery evaluation, required to reduce
morbidity from extremity and spinal deformities and other functional
burdens and to improve achievement of overall treatment outcomes?
13.For patients with FSS, SHS, DA1, or DA3, is dietectics consultation,
compared with general evaluation, appropriate to ensure adequate
nutritional intake?
14.For patients with FSS, SHS, DA1, or DA3, are cardiology and
pulmonology consultations, compared with general evaluation,
appropriate to reduce consequences of recurrent lower respiratory
infections and potential right heart strain?
15.For patients with FSS, SHS, DA1, and DA3 who have well vascularised
equinovarus resistant to non-operative treatment, should referral for
fabrication of prosthetic limb without amputation, compared with
Table 1 Actionable guiding clinical questions (Continued)
surgical intervention, be offered to improve achievement of overall
treatment outcomes?
16.Do patients with FSS, SHS, DA1, or DA3, compared with the general
population, have special problems that anaesthesia and general
emergency medicine providers must consider to expect reasonable
treatment-related decision-making and adverse-event free survival?
17.Do patients with FSS, SHS, DA1, or DA3, compared with the general
population, have special imaging findings and considerations that
radiologists and pathologists must be aware of that are relevant to
improving treatment-related decision-making?
18.For patients who may have a risk for a FSS, SHS, DA1, or DA3
pregnancy, is genetic counselling, pre-conception molecular testing,
post-conception molecular testing, prenatal ultrasound, or elective
abortion reasonably expected to improve decision-making and quality
of life outcomes?
19.For delivery of an infant with suspected or confirmed FSS, SHS, DA1,
or DA3 or delivery in mother with FSS, SHS, DA1, or DA3, is elective
caesarian delivery, compared with vaginal delivery, reasonably expected
to reduce foetal and maternal distress and improve adverse-event free
survival?
Table 2 Search strategy for PubMed database
((((((((“Freeman-Sheldon syndrome”[Supplementary Concept] OR
“Freeman-Sheldon syndrome”[All Fields] OR “freeman sheldon
syndrome”[All Fields]) OR (“Distal arthrogryposis type 2B”[Supplementary
Concept] OR “Distal arthrogryposis type 2B”[All Fields] OR “sheldon hall
syndrome”[All Fields])) OR Freeman-Sheldon[All Fields]) OR “distal
arthrogryposis multiplex congenita”[All Fields] OR (“Freeman-Sheldon
syndrome”[Supplementary Concept] OR "Freeman-Sheldon syndrome”[All
Fields] OR “whistling face syndrome”[All Fields])) OR (“Freeman-Sheldon
syndrome”[Supplementary Concept] OR “Freeman-Sheldon syndrome”[All
Fields] OR “craniocarpotarsal dystrophy”[All Fields])) OR (“Freeman-Sheldon
syndrome”[Supplementary Concept] OR “Freeman-Sheldon syndrome”[All
Fields] OR “craniocarpotarsal dysplasia”[All Fields])) OR (cranio-carpo-tarsal
[All Fields] AND dystrophy[All Fields])) OR (cranio-carpo-tarsal[All Fields]
AND dysplasia[All Fields])) OR (cranio-facio-corporal[All Fields] AND “
syndrome”[MeSH Terms])
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compared, due to high inter-patient and inter-
intervention variability. It is not certain that many of the
guiding questions will be able to be answered, and the
objectives more clearly reflect expectations for what data
will be available. There are no restrictions on patient
gender, ethnicity, geographical location, religion, socio-
economic status, or clinical setting. Most non-English
language articles are reviewed by native speakers (Span-
ish) or translated (Russian, Czech, German) in-house.
Asian language articles are unable to be reviewed or
translated in-house and are excluded.
Data extraction
As searches are carried out, citations of unique results
are placed in spreadsheets using the current iteration of
Google Sheets (Mountain View, CA) for initial inde-
pendent screening by two review authors to identify
those potentially meeting the inclusion criteria. After ini-
tial screening, articles retrieved are independently
assessed by two review authors for eligibility before in-
clusion. Discrepancies and disagreements are resolved
through discussion, with a third reviewer, or with the
ethics director or his designee. Authors of articles being
considered are not contacted with data queries. Only
published reports of patients, living or deceased, of any
age with a stated diagnosis of FSS, SHS, DA1, or DA3
are considered for initial inclusion. Published reports of
patients without a stated diagnosis of FSS, SHS, DA1, or
DA3 are not considered. Because of previously published
reports of diagnostic unreliability for FSS, SHS, DA1, or
DA3, only articles with sufficient patient-level clinical in-
formation for diagnosis verification are included in the
full analysis. Physical findings not evident in the article
text are recorded as present, if they are visible in accom-
panying figures; similarly, if it is clear that a certain
physical feature was absent in accompanying figures, it
is recorded as not present. Physical findings or historical
data present in fewer than five cases are not recorded,
and some physical findings or historical data items rela-
tively similar to each other and affecting fewer than five
individuals are combined into a single variable. Physical
findings or historical data not present or missing for a
given variable in a particular patient are both coded as
missing. Physical findings are evaluated and described
following the Elements of Morphology: Human Malfor-
mation Terminology [9–15].
Patient-level clinical information from included studies
is extrapolated, based on the standardised Survey of
Treatment Outcomes and Practices–Freeman-Sheldon
syndrome (STOP-FSS) questionnaire, and entered on a
spreadsheet (Google Sheets, Mountain View, CA) for
quality assessment and data synthesis. One review
author extracts data for each half of the final total of in-
cluded articles, with another review author verifying data
the other review author had entered and coded. The re-
view authors then discuss any differences in their re-
spective appraisals, with discrepancies discussed with a
third review author or with the ethics director or his
designee.
General types of patient-level clinical information
sought (Tables 3 and 4) include published diagnosis,
medical speciality of main author, patient congruence
with Stevenson criteria [3], demographics, pregnancy
complications, birth data, syndromic or potentially syn-
dromic physical findings and their complications, treat-
ment types, anaesthesia types, and overall treatment
outcome. Treatments for which data are sought include
treatments for any condition or feature actually or po-
tentially complicated by or associated with (primarily or
secondarily) FSS, SHS, DA1, or DA3. Such interventions
include surgery, physical therapy, and any other orga-
nised action to improve health or well-being. Overall
treatment outcome is a subjective clinical interpretation
by the review authors based on clinical data or opinions
presented in the manuscript; patient perception of out-
come, if presented in the manuscript, is not considered
by the review authors.
Risk of Bias (Quality) Assessment
Because of the limitations of case reports, biased risk is
not able to be formally assessed, particularly since the
quality of case reports and patient data contained
Table 3 Variables collected on unique papers. Table lists
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Table 4 Variables collected for individual patients. Table lists all







Year of publication Microstomia Seizures
Paper code
(in-house tracking)







scan (Give findings, if stated)













Other diagnosis Neck webbing Normal intelligence




































Karyotype results Mask-like face
Inheritance status Flat mid-face
Inheritance pattern Bulging forehead
Parental consanguinity Full forehead
Birth order Superior blepharoptosis
Total number of sibship Ophthalmoplegia
Maternal age at birth Blepharophimosis
Paternal age at birth Downslating palpebral
fissures
Gestation (weeks) Short palpebral fissures
Gestation (if stated as term
or non-term)
Epicanthal folds
Mother’s pregnancy illness Telecanthus
Prenatal polyhydramnios Ocular hypertelorism
Table 4 Variables collected for individual patients. Table lists all
items for which patient data are sought (Continued)
Cardiac abnormalities Deep set eyes
Caesarean section Prominent supracilliary
ridges
Vaginal delivery Symetrical subcutaneous
elevations of medial
frontal areas










Birth weight (kg) Small nose
Birth weight (if stated as
‘low’ but not given)
Broad nasal root
Birth height (cm) Broad/depressed nasal
bridge
Birth head circumference Long philtrum
Postnatal growth Microglossia
Failure-to-thrive Micrognathia
Most recent weight (kg) Retrognathia
Most recent weight (if
stated as ‘low’ but not
given)
Straight mandibular rami
Most recent stature (cm) Dental crowding
Most recent stature (if
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therein vary widely. As inter-case variability is signifi-
cant, case report quality assessment is mostly a clinical
decision by one review author and reviewed by a second,
based on reviewer knowledge of the syndromes, relative
agreement with consensus-based clinical case reporting
guideline enough to establish an accurate clinical picture
[16], and general clinical experience. In determining spe-
ciality of the main author, ambiguity can result, as not
all journals report the same type of author information,
and certain other judgements, such as overall treatment
outcome, are subjective and prone to bias of the original
and review authors. Concerns are discussed with a third
review author or with the ethics director or his designee.
Strategy for data synthesis
Most data extracted and generated for this review are
nominal, representing binary coding of clinical findings
and history to indicate the presence, absence, or non-
reporting of each variable sought. Because of high vari-
ability of physical features and historical data reported,
the small volume of published reports, and anticipated
poor diagnostic accuracy in published articles, classic
meta-analysis is not possible. Patient-level data are ag-
gregated into a single sample.
Statistical significance for all tests is calculated based
on a two-tailed alpha level of 0.05. Chi-squared analysis
Table 4 Variables collected for individual patients. Table lists all













































Early death (state cause)
MYBPC1 allelic variation
TPM2 allelic variation
Table 4 Variables collected for individual patients. Table lists all
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is used for nominal data, such as physical features or
specific aspects of the history. For higher order data,
such as measurements and ages, an independent group t
test or one-way or multiple-way between subject analysis
of variance tests is conducted. For each significant p
value, eta-squared or r-squared is calculated to deter-
mine effect size, as appropriate. Pearson correlation,
Tukey HSD, and linear regression analysis are also calcu-
lated and plotted, as appropriate, to evaluate possible as-
sociations between physical findings, specific aspects of
the history, treatment type, anaesthesia type, reported
and review author diagnosis, and overall treatment out-
come. No weighting of variables or models to account
for heterogenity are used. Subgroups are each analysed
individually in different data files. Data are analysed
using the current iterations of PSPP (The Free Software
Foundation, Boston, MA) and R: A Language and Envir-
onment for Statistical Computing (R Foundation for
Statistical Computing, Vienna, Austria) with R Com-
mander [17]. No special or additional commands are
used.
Analysis of subgroups or subsets
Data are analysed by the following diagnosis-related sub-
groups for both individual cases and papers: published
diagnosis, reviewer diagnosis of SHS, reviewer diagnosis
of FSS with only craniofacial features, reviewer diagnosis
of FSS with craniofacial and upper or lower limb malfor-
mations, reviewer diagnosis of FSS with craniofacial and
neurological features, and reviewer diagnosis of FSS
meeting the full Stevenson criteria [3]. Additionally, the
following additional groups are analysed: treatment type,
anaesthesia type, treatment outcome, all included cases,
all reviewer-diagnosed FSS cases, all retrieved papers,
and all included papers fully analysed. Data are also ana-
lysed by published diagnosis grouped by major speciality
(i.e. paediatrics, medical genetics, plastic surgery, ortho-
paedics, and anaesthetics) of the main author. Article
focus, journal focus and audience, author affiliation, and
Google searches of main authors are used by the review
authors to make judgements about speciality. This sys-
tematic review is undertaken concurrently with an on-
going retrospective cohort study using similar data syn-
thesis procedures (NCT01144741).
Discussion
We expect the need for high quality, detailed patient-
level clinical information will limit the effectiveness of
this project in assessing the review objectives with any
level of reasonable confidence, but we feel this is an ac-
ceptable beginning point. Most articles are expected to
demonstrate considerable variability in quality of case
reports generally, clarity of writing, presence and clarity
of accompanying pictorial evidence, details of treatment
and outcomes, psychosocial health descriptions, variabil-
ity of descriptive terminology, and attention to clinical
detail and accuracy. All present considerable obstacles,
complicating data extraction, coding, and analysis efforts
and severely limited significance, power, and utility of
the project’s results. The span of years and countries in-
cluded in the search present additional difficulties of his-
torical context. For example, articles from pre-DNA in
the 1930s in England, pre-human genome in the 1980s
in Germany, and post-human genome in the 2010s in
USA all present patients from differing perspectives and
emphasise different aspects of the history, findings, and
therapy. Cultural bias, focus of clinical attention, and
language each modify text and presentation of articles as
well.
We hope this project will begin to enable a more clear
outline of knowledge gaps and help prioritise areas for
clinical investigation. We feel our methodology may be
applicable and helpful for others investigating a condi-
tion or phenomena with similar difficulties present in
the existing literature that precludes conventional meta-
analysis.
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